
We are building an unprecedented pipeline of synergistic genomic medicines in the ocular space to bring relief to inherited retinal disease patients.
Our Portfolio
SPVN06
SparingVision’s lead product, SPVN06, is a breakthrough gene therapy approach targeting Inherited Retinal Diseases (IRDs).
Learn More